Imperial College London
Portrait Picture

ProfessorPaulKellam

Faculty of Medicine, Department of Infectious Disease

Professor of Virus Genomics
 
 
 
//

Contact

 

p.kellam

 
 
//

Location

 

460Wright Fleming WingSt Mary's Campus

//

Summary

 

Publications

Citation

BibTex format

@article{Post:2020:10.1371/journal.pone.0244126,
author = {Post, N and Eddy, D and Huntley, C and van, Schalkwyk M and Shrotri, M and Leeman, D and Rigby, S and Williams, S and Bermingham, W and Kellam, P and Maher, J and Shields, A and Amirthalingam, G and Peacock, S and Ismail, S},
doi = {10.1371/journal.pone.0244126},
journal = {PLoS One},
pages = {1--27},
title = {Antibody response to SARS-CoV-2 infection in humans: a systematic review},
url = {http://dx.doi.org/10.1371/journal.pone.0244126},
volume = {15},
year = {2020}
}
Download

RIS format (EndNote, RefMan)

TY  - JOUR
AB  - BackgroundProgress in characterising the humoral immune response to Severe Acute Respiratory Syndrome 2 (SARS-CoV-2) has been rapid but areas of uncertainty persist. Assessment of the full range of evidence generated to date to understand the characteristics of the antibody response, its dynamics over time, its determinants and the immunity it confers will have a range of clinical and policy implications for this novel pathogen. This review comprehensively evaluated evidence describing the antibody response to SARS-CoV-2 published from 01/01/2020-26/06/2020.MethodsSystematic review. Keyword-structured searches were carried out in MEDLINE, Embase and COVID-19 Primer. Articles were independently screened on title, abstract and full text by two researchers, with arbitration of disagreements. Data were double-extracted into a pre-designed template, and studies critically appraised using a modified version of the MetaQAT tool, with resolution of disagreements by consensus. Findings were narratively synthesised. Results150 papers were included. Most studies (113 or 75%) were observational in design, were based wholly or primarily on data from hospitalised patients (108, 72%) and had important methodological limitations. Few considered mild or asymptomatic infection. Antibody dynamics were well described in the acute phase, up to around 3 months from disease onset, but the picture regarding correlates of the antibody response was inconsistent. IgM was consistently detected before IgG in included studies, peaking at weeks 2-5 and declining over a further 3-5 weeks post-symptom onset depending on the patient group; IgG peaked around weeks 3-7 post-symptom onset then plateaued, generally persisting for at least 8 weeks. Neutralising antibodies were detectable within 7-15 days following disease onset, with levels increasing until days 14-22 before levelling and then decreasing, but titres were lower in those with asymptomatic or clinically mild disease. Specific and potent neu
AU  - Post,N
AU  - Eddy,D
AU  - Huntley,C
AU  - van,Schalkwyk M
AU  - Shrotri,M
AU  - Leeman,D
AU  - Rigby,S
AU  - Williams,S
AU  - Bermingham,W
AU  - Kellam,P
AU  - Maher,J
AU  - Shields,A
AU  - Amirthalingam,G
AU  - Peacock,S
AU  - Ismail,S
DO  - 10.1371/journal.pone.0244126
EP  - 27
PY  - 2020///
SN  - 1932-6203
SP  - 1
TI  - Antibody response to SARS-CoV-2 infection in humans: a systematic review
T2  - PLoS One
UR  - http://dx.doi.org/10.1371/journal.pone.0244126
UR  - https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0244126
UR  - http://hdl.handle.net/10044/1/84809
VL  - 15
ER  -
Download